Nocathiacins, New Thiazolyl Peptide Antibiotics from Nocardia sp. I. Taxonomy, Fermentation and Biological Activities.

Wenying Li(Bristol-Myers Squibb (Germany)), John E. Leet(Bristol-Myers Squibb (Germany)), HELEN A. AX(Bristol-Myers Squibb (Germany)), DONALD R. GUSTAVSON(Bristol-Myers Squibb (Germany)), D. M. Brown(Bristol-Myers Squibb (Germany)), Laura Turner(Bristol-Myers Squibb (Germany)), Kimberly Brown(Bristol-Myers Squibb (Germany)), Junius M. Clark(Bristol-Myers Squibb (Germany)), Hyekyung Yang(Bristol-Myers Squibb (Germany)), J Fung-Tomc(Bristol-Myers Squibb (Germany)), Kin S. Lam(Bristol-Myers Squibb (Germany))
The Journal of Antibiotics
January 1, 2003
Cited by 122Open Access
Full Text

Abstract

Thiazolyl peptide antibiotics, nocathiacin I, II and III, were identified in a culture of Nocardia sp. WW-12651 (ATCC 202099). They exhibit potent in vitro activity (ng/ml) against a wide spectrum of gram-positive bacteria, including multiple-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Enterococcus faecium (MREF) and fully penicillin-resistant Streptococcus pneumoniae (PRSP), and demonstrate excellent in vivo efficacy in a systemic Staphylococcus aureus infection mice model.


Related Papers

No related papers found

Powered by citation graph analysis